Abstract
In a phase III trial, olaparib maintenance therapy significantly extended progression-free survival and duration of response in patients with BRCA-mutated metastatic pancreatic cancer who responded to platinum-based chemotherapy, compared with a placebo. Based on the findings, which were presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, maintenance olaparib is likely to become a new treatment option for these patients.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
August 2019
Volume 9, Issue 8
Volume 9, Issue 8
Maintenance Olaparib New Standard in Pancreatic Cancer?
Jump to section
Advertisement